Agonist and antagonist effects of aripiprazole on D2-like receptors controlling rat brain dopamine synthesis depend on the dopaminergic tone

International Journal of Neuropsychopharmacology

Volumn 18, Issue 4, 2014, Pages 1-9

  Ma, Guo Fen ^a   Raivio, Noora ^a   Sabrià, Josefa ^a   Ortiz, Jordi ^a  

^a INSTITUT DE NEUROCIÈNCIES   (Spain)

Author keywords

GPCR; Intrinsic activity; Intrinsic efficacy; Schizophrenia; Striatum

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; PRECLAMOL; QUINPIROLE; AUTORECEPTOR; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; PIPERIDINE DERIVATIVE; POTASSIUM;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFICACY; EX VIVO STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC50; MALE; NONHUMAN; PARTIAL AGONISM; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CORPUS STRIATUM; DRUG EFFECTS; METABOLISM; NERVE ENDING; SPRAGUE DAWLEY RAT;

ANIMALS; ARIPIPRAZOLE; AUTORECEPTORS; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE D2 RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PIPERIDINES; POTASSIUM; PRESYNAPTIC TERMINALS; QUINPIROLE; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2;

EID: 84939159714     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyu046     Document Type: Article

References (38)

1. Anzalone A, Lizardi-Ortiz JE, Ramos M, De Mei C, Hopf FW, Iaccarino C, Halbout B, Jacobsen J, Kinoshita C, Welter M, Caron MG, Bonci A, Sulzer D, Borrelli E (2012) Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors. J Neurosci 32:9023-9034.
2. Bortolozzi A, Díaz-Mataix L, Toth M, Celada P, Artigas F (2007) In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl) 191:745-758.
3. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389.
4. Clark D, Hjorth S, Carlsson A. (1985) Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm. 62:1-52.
5. Di Matteo V, De Blasi A, Di Giulio C, Esposito E (2001) Role of 5-HT2C receptors in the control of central dopamine function. Trends Pharmacol Sci 22:229-232.
6. Gonzalez-Sepulveda M, Rosell S, Hoffmann HA, Castillo-Ruiz MM, Mignon V, Moreno-Delgado D, Vignes M, Diaz J, Sabria, Ortiz J (2013) Cellular distribution of the histamine H3 receptor in the basal ganglia: functional modulation of dopamine and glutamate neurotransmission. Basal Ganglia 3:109-121.
7. Iñiguez SD, Cortez AM, Crawford CA, McDougall SA (2008) Effects of aripiprazole and terguride on dopamine synthesis in the dorsal striatum and medial prefrontal cortex of preweanling rats. J Neural Transm 115:97-106.
8. Johnson EA, Fox JL, Azzaro AJ (1996) The anxiolytic serotonin 5-HT1A receptor agonists buspirone, ipsapirone and gepirone are inhibitors of tyrosine hydroxylation in rat striatum. Behav Brain Res 73:331-335.
9. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441:137-140.
10. Kehne JH, Andree TH, Heinrich JN (2008) D2 receptor partial agonists: treatment of CNS disorders of dopamine function. Curr Top Med Chem 8:1068-1088 Kenakin TP, Morgan PH (1989) Theoretical effects of single and multiple transducer receptor coupling proteins on estimates of the relative potency of agonists. Mol Pharmacol 35:214-222.
11. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S (1995) 7-(4-[4-(2, 3-Dichlorophenyl)-1-piperazinyl] butyloxy)-3, 4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274:329-336.
12. Koener B, Focant MC, Bosier B, Maloteaux JM, Hermans E (2012) Increasing the density of the D2L receptor and manipulating the receptor environment are required to evidence the partial agonist properties of aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 36:60-70.
13. Kuroki T, Dai J, Meltzer HY, Ichikawa J (2000) R(+)-8-OH-DPAT, a selective 5-HT1A receptor agonist, attenuated amphetamineinduced dopamine synthesis in rat striatum, but not nucleus accumbens or medial prefrontal cortex. Brain Res 872:204-207.
14. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA. (1998) Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-npropylpiperidine( preclamol) in schizophrenia. Biol Psychiatry 43:2-11.
15. Largent BL, Wikström H, Gundlach AL, Snyder SH (1987) Structural determinants of sigma receptor affinity. Mol Pharmacol 32:772-784.
16. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627.
17. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second- generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41.
18. Maggio R, Millan MJ (2010) Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. Curr Opin Pharmacol 10:100-107.
19. Mailman RB (2007) GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 28:390-396.
20. Mailman RB, Murphy V (2010) Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 16:488-501.
21. Meller E, Bohmaker K, Namba Y, Friedhoff AJ, Goldstein M (1987) Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol Pharmacol 31:592-598.
22. Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR, Booth RG, Hyslop DK, Piercey M, Wightman RM, Lawler CP, Nichols DE, Mailman RB (2002) Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 301:1166-1178.
23. Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S (2011) Partial agonists in schizophrenia-why some work and others do not: insights from preclinical animal models. Int J Neuropsychopharmacol 14:1165-1178.
24. Navarro G, Moreno E, Bonaventura J, Brugarolas M, Farré D, Aguinaga D, Mallol J, Cortés A, Casadó V, Lluís C, Ferre S, Franco R, Canela E, McCormick PJ (2013) Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers. PLoS One 8:e61245.
25. Safer DJ, Calarge CA, Safer AM (2013) Prolactin serum concentrations during aripiprazole treatment in youth. J Child Adolesc Psychopharmacol 23:282-289.
26. Sahlholm K, Barchad-Avitzur O, Marcellino D, Gómez-Soler M, Fuxe K, Ciruela F, Arhem P (2011) Agonist-specific voltage sensitivity at the dopamine D2S receptor-molecular determinants and relevance to therapeutic ligands. Neuropharmacology 61:937-949.
27. Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38.
28. Seeman P (2005) An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry 162:1984-1985.
29. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411.
30. Tadori Y, Miwa T, Tottori K, Burris KD, Stark A, Mori T, Kikuchi T. (2005) Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol 515:10-19.
31. Tadori Y, Forbes RA, McQuade RD, Kikuchi T (2009) Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol 607:35-40.
32. Tadori Y, Forbes RA, McQuade RD, Kikuchi T (2011a) Functional potencies of dopamine agonists and antagonists at human dopamine D2 and D3 receptors. Eur J Pharmacol 666:43-52.
33. Tadori Y, Forbes RA, McQuade RD, Kikuchi T (2011b) In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol 668:355-365.
34. Tamminga CA (2002) Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109:411-420.
35. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB (2007a) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13.
36. Urban JD, Vargas GA, von Zastrow M, Mailman RB (2007b) Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 32:67-77.
37. Usiello A, Baik JH, Rougé-Pont F, Picetti R, Dierich A, LeMeur M, Piazza PV, Borrelli E (2000) Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408:199-203.
38. Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF (2002) Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27:248-259.